Metastatic Castration-Sensitive Prostate Cancer research hub

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

This study is testing a new drug, Saruparib, for men with advanced prostate cancer that is still responding to hormone treatment. It aims to see if adding Saruparib to standard hormone therapy works better than standard therapy alone to slow down cancer growth.